Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.
Identifieur interne : 000467 ( Main/Exploration ); précédent : 000466; suivant : 000468Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.
Auteurs : Carolina Simioni [Italie] ; Alberto M. Martelli [Italie] ; Giorgio Zauli [Italie] ; Marco Vitale [Italie] ; James A. Mccubrey [États-Unis] ; Silvano Capitani [Italie] ; Luca M. Neri [Italie]Source :
- Journal of cellular physiology [ 1097-4652 ] ; 2018.
Descripteurs français
- KwdFr :
- Humains (MeSH), Leucémie-lymphome lymphoblastique à précurseurs B et T (anatomopathologie), Leucémie-lymphome lymphoblastique à précurseurs B et T (génétique), Leucémie-lymphome lymphoblastique à précurseurs B et T (traitement médicamenteux), Lymphocytes B (anatomopathologie), Phosphatidylinositol 3-kinase (génétique), Protéines proto-oncogènes c-akt (antagonistes et inhibiteurs), Protéines proto-oncogènes c-akt (génétique), Résistance aux médicaments antinéoplasiques (génétique), Sirolimus (usage thérapeutique), Synergie des médicaments (MeSH), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Sérine-thréonine kinases TOR (génétique), Thérapie moléculaire ciblée (MeSH), Transduction du signal (effets des médicaments et des substances chimiques).
- MESH :
- anatomopathologie : Leucémie-lymphome lymphoblastique à précurseurs B et T, Lymphocytes B.
- antagonistes et inhibiteurs : Protéines proto-oncogènes c-akt, Sérine-thréonine kinases TOR.
- effets des médicaments et des substances chimiques : Transduction du signal.
- génétique : Leucémie-lymphome lymphoblastique à précurseurs B et T, Phosphatidylinositol 3-kinase, Protéines proto-oncogènes c-akt, Résistance aux médicaments antinéoplasiques, Sérine-thréonine kinases TOR.
- traitement médicamenteux : Leucémie-lymphome lymphoblastique à précurseurs B et T.
- usage thérapeutique : Sirolimus.
- Humains, Synergie des médicaments, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- B-Lymphocytes (pathology), Drug Resistance, Neoplasm (genetics), Drug Synergism (MeSH), Humans (MeSH), Molecular Targeted Therapy (MeSH), Phosphatidylinositol 3-Kinase (genetics), Phosphoinositide-3 Kinase Inhibitors (MeSH), Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy), Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics), Precursor Cell Lymphoblastic Leukemia-Lymphoma (pathology), Proto-Oncogene Proteins c-akt (antagonists & inhibitors), Proto-Oncogene Proteins c-akt (genetics), Signal Transduction (drug effects), Sirolimus (therapeutic use), TOR Serine-Threonine Kinases (antagonists & inhibitors), TOR Serine-Threonine Kinases (genetics).
- MESH :
- chemical , antagonists & inhibitors : Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases.
- chemical , genetics : Phosphatidylinositol 3-Kinase, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases.
- drug effects : Signal Transduction.
- drug therapy : Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- genetics : Drug Resistance, Neoplasm, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- pathology : B-Lymphocytes, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- chemical , therapeutic use : Sirolimus.
- Drug Synergism, Humans, Molecular Targeted Therapy, Phosphoinositide-3 Kinase Inhibitors.
Abstract
Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15-20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from chemo- and radiation therapy, including secondary malignancies, are a growing problem for leukemia survivors. Targeted therapy holds promising perspectives for cancer treatment as it may be more effective and have fewer side effects than conventional therapies. The phosphatidylinositol 3-phosphate kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathway is a key regulatory cascade which controls proliferation, survival and drug-resistance of cancer cells, and it is frequently upregulated in the different subtypes of B-ALL, where it plays important roles in the pathophysiology, maintenance and progression of the disease. Moreover, activation of this signaling cascade portends a poorer prognosis in both pediatric and adult B-ALL patients. Promising preclinical data on PI3K/Akt/mTOR inhibitors have documented their anticancer activity in B-ALL and some of these novel drugs have entered clinical trials as they could lead to a longer event-free survival and reduce therapy-associated toxicity for patients with B-ALL. This review highlights the current status of PI3K/Akt/mTOR inhibitors in B-ALL, with an emphasis on emerging evidence of the superior efficacy of synergistic combinations involving the use of traditional chemotherapeutics or other novel, targeted agents.
DOI: 10.1002/jcp.26539
PubMed: 29667769
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.</title><author><name sortKey="Simioni, Carolina" sort="Simioni, Carolina" uniqKey="Simioni C" first="Carolina" last="Simioni">Carolina Simioni</name><affiliation wicri:level="1"><nlm:affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Zauli, Giorgio" sort="Zauli, Giorgio" uniqKey="Zauli G" first="Giorgio" last="Zauli">Giorgio Zauli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Vitale, Marco" sort="Vitale, Marco" uniqKey="Vitale M" first="Marco" last="Vitale">Marco Vitale</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Surgery, University of Parma, Parma</wicri:regionArea><wicri:noRegion>Parma</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>CoreLab, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>CoreLab, Azienda Ospedaliero-Universitaria di Parma, Parma</wicri:regionArea><wicri:noRegion>Parma</wicri:noRegion></affiliation></author><author><name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville</wicri:cityArea></affiliation></author><author><name sortKey="Capitani, Silvano" sort="Capitani, Silvano" uniqKey="Capitani S" first="Silvano" last="Capitani">Silvano Capitani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Neri, Luca M" sort="Neri, Luca M" uniqKey="Neri L" first="Luca M" last="Neri">Luca M. Neri</name><affiliation wicri:level="1"><nlm:affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29667769</idno><idno type="pmid">29667769</idno><idno type="doi">10.1002/jcp.26539</idno><idno type="wicri:Area/Main/Corpus">000574</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000574</idno><idno type="wicri:Area/Main/Curation">000574</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000574</idno><idno type="wicri:Area/Main/Exploration">000574</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.</title><author><name sortKey="Simioni, Carolina" sort="Simioni, Carolina" uniqKey="Simioni C" first="Carolina" last="Simioni">Carolina Simioni</name><affiliation wicri:level="1"><nlm:affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Zauli, Giorgio" sort="Zauli, Giorgio" uniqKey="Zauli G" first="Giorgio" last="Zauli">Giorgio Zauli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Vitale, Marco" sort="Vitale, Marco" uniqKey="Vitale M" first="Marco" last="Vitale">Marco Vitale</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Surgery, University of Parma, Parma</wicri:regionArea><wicri:noRegion>Parma</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>CoreLab, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>CoreLab, Azienda Ospedaliero-Universitaria di Parma, Parma</wicri:regionArea><wicri:noRegion>Parma</wicri:noRegion></affiliation></author><author><name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville</wicri:cityArea></affiliation></author><author><name sortKey="Capitani, Silvano" sort="Capitani, Silvano" uniqKey="Capitani S" first="Silvano" last="Capitani">Silvano Capitani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Neri, Luca M" sort="Neri, Luca M" uniqKey="Neri L" first="Luca M" last="Neri">Luca M. Neri</name><affiliation wicri:level="1"><nlm:affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of cellular physiology</title><idno type="eISSN">1097-4652</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>B-Lymphocytes (pathology)</term><term>Drug Resistance, Neoplasm (genetics)</term><term>Drug Synergism (MeSH)</term><term>Humans (MeSH)</term><term>Molecular Targeted Therapy (MeSH)</term><term>Phosphatidylinositol 3-Kinase (genetics)</term><term>Phosphoinositide-3 Kinase Inhibitors (MeSH)</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics)</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (pathology)</term><term>Proto-Oncogene Proteins c-akt (antagonists & inhibitors)</term><term>Proto-Oncogene Proteins c-akt (genetics)</term><term>Signal Transduction (drug effects)</term><term>Sirolimus (therapeutic use)</term><term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term><term>TOR Serine-Threonine Kinases (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Humains (MeSH)</term><term>Leucémie-lymphome lymphoblastique à précurseurs B et T (anatomopathologie)</term><term>Leucémie-lymphome lymphoblastique à précurseurs B et T (génétique)</term><term>Leucémie-lymphome lymphoblastique à précurseurs B et T (traitement médicamenteux)</term><term>Lymphocytes B (anatomopathologie)</term><term>Phosphatidylinositol 3-kinase (génétique)</term><term>Protéines proto-oncogènes c-akt (antagonistes et inhibiteurs)</term><term>Protéines proto-oncogènes c-akt (génétique)</term><term>Résistance aux médicaments antinéoplasiques (génétique)</term><term>Sirolimus (usage thérapeutique)</term><term>Synergie des médicaments (MeSH)</term><term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term><term>Sérine-thréonine kinases TOR (génétique)</term><term>Thérapie moléculaire ciblée (MeSH)</term><term>Transduction du signal (effets des médicaments et des substances chimiques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Proto-Oncogene Proteins c-akt</term><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Phosphatidylinositol 3-Kinase</term><term>Proto-Oncogene Proteins c-akt</term><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term><term>Lymphocytes B</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines proto-oncogènes c-akt</term><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Transduction du signal</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Neoplasm</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term><term>Phosphatidylinositol 3-kinase</term><term>Protéines proto-oncogènes c-akt</term><term>Résistance aux médicaments antinéoplasiques</term><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>B-Lymphocytes</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Sirolimus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Synergism</term><term>Humans</term><term>Molecular Targeted Therapy</term><term>Phosphoinositide-3 Kinase Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Synergie des médicaments</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15-20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from chemo- and radiation therapy, including secondary malignancies, are a growing problem for leukemia survivors. Targeted therapy holds promising perspectives for cancer treatment as it may be more effective and have fewer side effects than conventional therapies. The phosphatidylinositol 3-phosphate kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathway is a key regulatory cascade which controls proliferation, survival and drug-resistance of cancer cells, and it is frequently upregulated in the different subtypes of B-ALL, where it plays important roles in the pathophysiology, maintenance and progression of the disease. Moreover, activation of this signaling cascade portends a poorer prognosis in both pediatric and adult B-ALL patients. Promising preclinical data on PI3K/Akt/mTOR inhibitors have documented their anticancer activity in B-ALL and some of these novel drugs have entered clinical trials as they could lead to a longer event-free survival and reduce therapy-associated toxicity for patients with B-ALL. This review highlights the current status of PI3K/Akt/mTOR inhibitors in B-ALL, with an emphasis on emerging evidence of the superior efficacy of synergistic combinations involving the use of traditional chemotherapeutics or other novel, targeted agents.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29667769</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4652</ISSN><JournalIssue CitedMedium="Internet"><Volume>233</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>10</Month></PubDate></JournalIssue><Title>Journal of cellular physiology</Title><ISOAbbreviation>J Cell Physiol</ISOAbbreviation></Journal><ArticleTitle>Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.</ArticleTitle><Pagination><MedlinePgn>6440-6454</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jcp.26539</ELocationID><Abstract><AbstractText>Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15-20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from chemo- and radiation therapy, including secondary malignancies, are a growing problem for leukemia survivors. Targeted therapy holds promising perspectives for cancer treatment as it may be more effective and have fewer side effects than conventional therapies. The phosphatidylinositol 3-phosphate kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathway is a key regulatory cascade which controls proliferation, survival and drug-resistance of cancer cells, and it is frequently upregulated in the different subtypes of B-ALL, where it plays important roles in the pathophysiology, maintenance and progression of the disease. Moreover, activation of this signaling cascade portends a poorer prognosis in both pediatric and adult B-ALL patients. Promising preclinical data on PI3K/Akt/mTOR inhibitors have documented their anticancer activity in B-ALL and some of these novel drugs have entered clinical trials as they could lead to a longer event-free survival and reduce therapy-associated toxicity for patients with B-ALL. This review highlights the current status of PI3K/Akt/mTOR inhibitors in B-ALL, with an emphasis on emerging evidence of the superior efficacy of synergistic combinations involving the use of traditional chemotherapeutics or other novel, targeted agents.</AbstractText><CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simioni</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelli</LastName><ForeName>Alberto M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zauli</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitale</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CoreLab, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCubrey</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capitani</LastName><ForeName>Silvano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neri</LastName><ForeName>Luca M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-7924-1477</Identifier><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Physiol</MedlineTA><NlmUniqueID>0050222</NlmUniqueID><ISSNLinking>0021-9541</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.137</RegistryNumber><NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054198" MajorTopicYN="N">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">B-ALL</Keyword><Keyword MajorTopicYN="Y">PI3K/Akt/mTOR signaling</Keyword><Keyword MajorTopicYN="Y">combination therapy</Keyword><Keyword MajorTopicYN="Y">protein kinase inhibitors</Keyword><Keyword MajorTopicYN="Y">targeted therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>02</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29667769</ArticleId><ArticleId IdType="doi">10.1002/jcp.26539</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li><li>États-Unis</li></country><region><li>Caroline du Nord</li></region></list><tree><country name="Italie"><noRegion><name sortKey="Simioni, Carolina" sort="Simioni, Carolina" uniqKey="Simioni C" first="Carolina" last="Simioni">Carolina Simioni</name></noRegion><name sortKey="Capitani, Silvano" sort="Capitani, Silvano" uniqKey="Capitani S" first="Silvano" last="Capitani">Silvano Capitani</name><name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name><name sortKey="Neri, Luca M" sort="Neri, Luca M" uniqKey="Neri L" first="Luca M" last="Neri">Luca M. Neri</name><name sortKey="Vitale, Marco" sort="Vitale, Marco" uniqKey="Vitale M" first="Marco" last="Vitale">Marco Vitale</name><name sortKey="Vitale, Marco" sort="Vitale, Marco" uniqKey="Vitale M" first="Marco" last="Vitale">Marco Vitale</name><name sortKey="Zauli, Giorgio" sort="Zauli, Giorgio" uniqKey="Zauli G" first="Giorgio" last="Zauli">Giorgio Zauli</name></country><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000467 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000467 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29667769
|texte= Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29667769" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |